Non-Profit CHDI Taps Galapagos For Developing Huntington's Disease Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
The philanthropy firm, like others of its ilk, seeks to accelerate early-stage R&D on a neglected disease.
You may also be interested in...
The Xenazine Model: Big Things Come In Small Packages
The Huntington's chorea therapy Xenazine (tetrabenazine) is being used by just over 1,000 patients after three months on the market, and Biovail couldn't be happier
Edinburgh-Based TPP Global Development Highlights Role of Scientific Advisors
Scottish drug development company, TPP Global Development, raises $14 million to pursue pre-clinical strategic plan